FOXO4-DRI
A senolytic peptide designed to selectively clear senescent cells by disrupting the FOXO4-p53 interaction, studied for anti-aging applications.
What is FOXO4-DRI?
FOXO4-DRI is a modified peptide designed to target and eliminate senescent cells — aged cells that no longer divide but release inflammatory signals that damage surrounding tissue. By disrupting the interaction between FOXO4 and p53 proteins, it may trigger senescent cells to undergo programmed cell death (apoptosis) while leaving healthy cells unaffected.
What FOXO4-DRI Is Investigated For
FOXO4-DRI is investigated as a senolytic peptide designed to selectively clear senescent cells by disrupting the FOXO4-p53 interaction, with proposed applications in age-related tissue decline, inflammation, and functional restoration in aging. The strongest evidence is the 2017 Cell paper from Peter de Keizer's group at Erasmus MC reporting that aged and chemotherapy-treated mice showed restoration of physical fitness, fur density, and renal function after FOXO4-DRI treatment, along with additional preclinical work in keloid fibroblasts, pulmonary fibrosis, aged Leydig cells, and in vitro chondrocytes. The honest caveats are overwhelming: no human clinical trial of any phase has been conducted nearly a decade after the foundational paper, human pharmacokinetics are uncharacterized, claimed selectivity is preferential rather than absolute, and the theoretical concern about off-target apoptosis in damaged-but-not-senescent cells remains unresolved. The broader senolytic field has moved forward primarily with small molecules (dasatinib + quercetin, fisetin, navitoclax) that have entered clinical trials; FOXO4-DRI has not. Any self-experimentation dose is extrapolated from mouse data that does not translate to humans.
History & Discovery
FOXO4-DRI was designed and characterized by Peter de Keizer's group at Erasmus MC in Rotterdam and published in a 2017 paper in Cell that became a landmark reference in the emerging senolytic field. The research question was why senescent cells — damaged cells that stop dividing but persist and secrete inflammatory signals (the SASP) — resist the apoptotic fate that would normally clear them. De Keizer and colleagues identified an interaction between FOXO4 and p53 in senescent cells that sequesters p53 in the nucleus and away from mitochondria, preventing the mitochondrial apoptosis pathway from triggering. They then designed a peptide to competitively disrupt that interaction. The peptide uses a D-retro-inverso design: the amino acid sequence is reversed and all L-amino acids are replaced with D-enantiomers. This structural trick preserves side-chain topology for binding while making the peptide almost entirely resistant to proteolytic degradation, substantially extending in-vivo availability. In aged and chemotherapy-treated mice, FOXO4-DRI produced reported restoration of physical fitness, fur density, and renal function, with preferential loss of senescent cells and minimal toxicity to healthy tissue. The translation from that 2017 mouse data to any human clinical program has not occurred. No Phase I, Phase II, or Phase III trials of FOXO4-DRI have been conducted. A small number of additional preclinical studies have explored specific tissue contexts — keloid fibroblasts, pulmonary fibrosis, aged Leydig cells, in vitro chondrocytes — but the translational gap from rodent and in-vitro findings to human therapeutic use remains complete. Nevertheless, FOXO4-DRI entered the research-chemical longevity-enthusiast market within a few years of the Cell paper and is used in self-experimentation protocols well outside any clinical framework.
How It Works
FOXO4-DRI works by blocking a protective signal that keeps damaged old cells alive. When this signal is disrupted, the body's natural cleanup processes can remove these harmful cells, potentially reducing inflammation and improving tissue function.
FOXO4-DRI is a D-retro-inverso peptide that competitively binds to p53, displacing endogenous FOXO4. In senescent cells, the FOXO4-p53 interaction is critical for maintaining viability by sequestering p53 away from mitochondria. When FOXO4-DRI disrupts this interaction, p53 is released to trigger mitochondrial-mediated apoptosis specifically in senescent cells, as healthy cells do not depend on this survival mechanism.
Evidence Snapshot
Human Clinical Evidence
Extremely limited. A few case reports and self-experimentation accounts exist, but no formal clinical trials have been conducted.
Animal / Preclinical
Promising. Mouse studies showed restoration of fitness, fur density, and renal function in aged mice after FOXO4-DRI treatment.
Mechanistic Rationale
Strong. The FOXO4-p53 axis in senescent cells is well-characterized, and the D-retro-inverso design provides protease resistance.
Research Gaps & Open Questions
What the current literature has not yet settled about FOXO4-DRI:
- 01No human clinical trials of any phase have been conducted. Human safety, dosing, pharmacokinetics, pharmacodynamics, and efficacy are all unestablished.
- 02Selectivity of senescent-cell clearance in humans — mouse data showed preferential targeting, but the extent to which this selectivity holds at different doses, across different human tissues, and in different disease states is unknown.
- 03Long-term consequences of senescent-cell clearance — senescent cells play roles in wound healing, tumor suppression, and tissue remodeling; aggressively clearing them may carry unanticipated consequences that the short-term mouse studies did not capture.
- 04Comparative performance versus small-molecule senolytics — dasatinib + quercetin, fisetin, and navitoclax have progressed into human trials, and FOXO4-DRI has not; head-to-head data is absent.
- 05Independent replication — the foundational effects rest heavily on the de Keizer group's work and a modest number of downstream preclinical papers; broader replication across research groups would strengthen confidence.
- 06Pharmacokinetics of D-retro-inverso peptides in humans — distribution, tissue penetration, elimination, and immunogenicity of this structural class are characterized in animal models but not in humans for FOXO4-DRI specifically.
Forms & Administration
FOXO4-DRI is typically discussed in the context of subcutaneous injection. Due to its D-amino acid composition, it has enhanced stability compared to L-peptides. Protocols are highly experimental. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no validated human dose. The de Keizer mouse studies used intraperitoneal doses of roughly 5 mg/kg given three times over a treatment cycle. Community self-experimentation protocols have extrapolated these to human mg-range doses (commonly described figures are in the range of 2–5 mg per injection), but direct mg/kg translation from mouse to human is not pharmacologically justified without clinical data, and the appropriate human dose is genuinely unknown.
Frequency
Preclinical mouse protocols typically used a short course of 3 doses over about a week, sometimes repeated at intervals of weeks to months. The senolytic concept is pulse-dosing rather than chronic dosing — the goal is to clear a population of senescent cells, not to maintain continuous receptor activation. Community self-experimentation mirrors this, typically describing single or few-dose protocols rather than daily use.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
If any convention has emerged, it is widely spaced pulses (every several weeks to months) rather than continuous cycling. There is no human-data basis for any specific schedule.
Protocol Notes
FOXO4-DRI is typically supplied as a lyophilized powder and reconstituted in bacteriostatic water for subcutaneous injection. The D-retro-inverso design provides substantial proteolytic stability, meaning reconstituted peptide is relatively robust compared with L-peptides. The core honest statement about dosing is that nothing is validated in humans. The self-experimentation community extrapolates mouse doses, adjusts for perceived tolerability, and shares anecdotes. Those anecdotes are not evidence. Known risks include the theoretical possibility of off-target apoptosis in cell populations that are not actually senescent — tissue-specific selective clearance was demonstrated in mouse models, but the fidelity of that selectivity at different doses in humans, across different tissues and disease states, has not been established. The senolytic field as a whole is moving forward with clinical trials (dasatinib + quercetin, navitoclax, UBX-series compounds), but FOXO4-DRI specifically has not been part of those programs.
FOXO4-DRI has never been tested in humans in any controlled trial. It is not FDA-approved. Any dose figures circulating in the community are extrapolated from mouse studies and are not validated. Mouse does not equal human — this is not a cliché; it is the central caveat.
Timeline of Effects
Onset
In the 2017 mouse studies, loss of senescent-cell markers and restoration of functional measures (physical activity, fur density, renal function) was documented over several weeks following a multi-dose treatment course. Whether any comparable time-course applies to humans is unknown.
Peak Effect
The senolytic framework proposes a durable effect after each clearance pulse, as long as the senescent-cell population remains cleared. In mice, functional improvements were sustained for weeks to months after a single treatment course, but eventually required re-dosing as new senescent cells accumulated. No human data characterizes this cycle.
After Discontinuation
The conceptual model is that the peptide clears and its direct pharmacologic effect ends within days given even enhanced D-peptide stability, but the biological effect — having cleared a cell population — persists until those cells are regenerated through normal aging processes. Whether this model is accurate in humans is not demonstrated.
Common Questions
Who FOXO4-DRI Is NOT For
- •Any cancer history — apoptosis-triggering peptides are pharmacologically adjacent to oncology therapeutics, and the interactions with active tumor biology, chemotherapy regimens, and post-cancer surveillance are not characterized.
- •Pregnancy and breastfeeding — no safety data of any kind; a peptide designed to trigger apoptosis in a specific cell population is categorically unsuitable for use during pregnancy or lactation absent rigorous reproductive toxicology.
- •Pediatric use (under 18) — no data and no appropriate indication; the senescent-cell burden in pediatric populations is categorically different from the aging context FOXO4-DRI was designed for.
- •Active autoimmune disease — senescent cells and the SASP interact with immune surveillance in ways that are not fully understood; perturbing this system with an off-label senolytic in active autoimmunity is imprudent.
- •Recent surgery or active wound healing — senescent cells play a transient role in wound healing, and senolytic pulses during active repair have not been studied for safety.
- •Known hypersensitivity to peptide therapeutics, D-peptides, or excipients used in reconstitution.
Drug & Supplement Interactions
Clinical drug interaction data for FOXO4-DRI is completely absent because no human clinical studies have been conducted. What follows is mechanistic speculation. The highest-risk theoretical interaction is with chemotherapy. The 2017 Cell paper demonstrated that FOXO4-DRI could clear therapy-induced senescent cells in mice receiving doxorubicin, but in a controlled preclinical protocol — outside that protocol, overlapping a senolytic with active cytotoxic chemotherapy in humans has not been safety-characterized, and off-target apoptosis in damaged-but-not-senescent cell populations is a real concern. Overlap with other senolytics (dasatinib + quercetin, fisetin, navitoclax) in combination is not studied and theoretically risks broader off-target apoptosis. Immunosuppressive medications interact with senescent-cell immune surveillance in complex ways. Anti-inflammatory medications may interact with the SASP-related effects the peptide is meant to attenuate. Patients on any active medication should disclose FOXO4-DRI use to their prescribing clinicians, and patients with any oncology history should not use the peptide outside a proper clinical research context.
Safety Profile
Common Side Effects
Cautions
- • Very limited human data
- • Not FDA-approved
- • Complex mechanism requires expert guidance
- • Potential for unintended cell death
What We Don't Know
Nearly all data comes from animal models. Human safety, dosing, and long-term effects are essentially unknown.
Legal Status
United States
FOXO4-DRI is not FDA-approved for any medical indication. It has never entered human clinical trials. It is sold through research-chemical suppliers labeled 'not for human use'; distribution for human consumption is unauthorized under the FD&C Act. It is not a scheduled controlled substance.
International
Not authorized as a medicine in the EU, UK, Canada, or Australia. Regulatory posture across developed markets treats it as an unapproved investigational agent.
Sports & Competition
FOXO4-DRI is not listed by name on the WADA Prohibited List. However, WADA category S0 prohibits any substance 'not currently approved by any governmental regulatory health authority for human therapeutic use' — a description that covers FOXO4-DRI. Athletes subject to WADA, USADA, UKAD, or equivalent frameworks should treat it as prohibited in and out of competition under S0, regardless of whether the specific peptide is named.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
FOXO4-DRI has been shown to reverse aging.
Reality
Mouse studies showed restoration of specific functional measures — physical activity, fur density, renal function — in aged and chemotherapy-treated mice. That is scientifically interesting. It is not 'reversing aging' in a comprehensive sense, and it is not a human finding. Extrapolating a headline-worthy rodent result into a claim about human aging reversal is not what the data supports.
Myth
The D-retro-inverso design makes FOXO4-DRI safe for long-term use in humans.
Reality
The DRI modification makes the peptide resistant to proteolytic degradation and extends in-vivo availability. It does not address the underlying pharmacologic and biological safety questions — off-target apoptosis, dose-response in humans, interactions with active disease processes, long-term immune and tissue consequences of repeated senolytic pulses. Stability is not safety.
Myth
If the mouse data looks this good, human data must be just around the corner.
Reality
The original paper was published in 2017. As of the most recent public information, no human clinical trial of FOXO4-DRI has been registered or initiated. The senolytic field is moving forward, but largely through small molecules rather than this specific peptide. 'Just around the corner' has been the framing for years, and it remains speculative.
Myth
FOXO4-DRI available from research-chemical suppliers is the same as what was used in the Erasmus MC studies.
Reality
The published studies used peptide produced under research-grade standards with identity, purity, and endotoxin specifications. Research-chemical market supply does not consistently meet those specifications, and misidentification or truncation of D-peptides is a documented market issue. Assuming equivalence is not warranted.
Myth
Because FOXO4-DRI selectively clears senescent cells, there is no meaningful risk to healthy cells.
Reality
Selectivity in the 2017 mouse data was preferential rather than absolute, and it was characterized at specific doses in specific biological contexts. Scaling to different doses, different tissues, different human disease states, and different concurrent therapies may change the selectivity profile in ways that have not been measured. Treating preferential selectivity as categorical safety is unsupported.
Published Research
8 studiesTargeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
The foundational 2017 Cell paper from Peter de Keizer's group that introduced FOXO4-DRI and demonstrated restored physical fitness, fur density, and renal function in aged and chemotherapy-treated mice. Every subsequent FOXO4-DRI paper builds on this work.
Quick Facts
- Class
- Senolytic Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- May 2026
- Citations
- 8PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.